» Articles » PMID: 36773054

Long COVID Could Become a Widespread Post-pandemic Disease? A Debate on the Organs Most Affected

Overview
Specialty Pharmacology
Date 2023 Feb 11
PMID 36773054
Authors
Affiliations
Soon will be listed here.
Abstract

Long COVID is an emerging problem in the current health care scenario. It is a syndrome with common symptoms of shortness of breath, fatigue, cognitive dysfunction, and other conditions that have a high impact on daily life. They are fluctuating or relapsing states that occur in patients with a history of SARS-CoV-2 infection for at least 2 months. They are usually conditions that at 3 months after onset cannot be explained by an alternative diagnosis. Currently very little is known about this syndrome. A thorough review of the literature highlights that the cause is attributable to deposits of tau protein. Massive phosphorylation of tau protein in response to SARS-CoV-2 infection occurred in brain samples from autopsies of people previously affected with COVID-19. The neurological disorders resulting from this clinical condition are termed tauopathies and can give different pathological symptoms depending on the involved anatomical region of the brain. Peripheral small-fiber neuropathies are also evident among patients with Long COVID leading to fatigue, which is the main symptom of this syndrome. Certainly more research studies could confirm the association between tau protein and Long COVID by defining the main role of tau protein as a biomarker for the diagnosis of this syndrome that is widespread in the post-pandemic period.

Citing Articles

Exploring the experiences of cognitive symptoms in Long COVID: a mixed-methods study in the UK.

Miller A, Song N, Sivan M, Chowdhury R, Burke M BMJ Open. 2025; 15(1):e084999.

PMID: 39863405 PMC: 11784330. DOI: 10.1136/bmjopen-2024-084999.


Pandemics: past, present, and future: multitasking challenges in need of cross-disciplinary, transdisciplinary, and multidisciplinary collaborative solutions.

Khorram-Manesh A, Burkle Jr F, Goniewicz K Osong Public Health Res Perspect. 2024; 15(4):267-285.

PMID: 39039818 PMC: 11391372. DOI: 10.24171/j.phrp.2023.0372.


Exploring the Pathophysiology of Long COVID: The Central Role of Low-Grade Inflammation and Multisystem Involvement.

Gusev E, Sarapultsev A Int J Mol Sci. 2024; 25(12).

PMID: 38928096 PMC: 11204317. DOI: 10.3390/ijms25126389.


Optimizing cardiopulmonary rehabilitation duration for long COVID patients: an exercise physiology monitoring approach.

Szarvas Z, Fekete M, Szollosi G, Kup K, Horvath R, Shimizu M Geroscience. 2024; 46(5):4163-4183.

PMID: 38771423 PMC: 11336035. DOI: 10.1007/s11357-024-01179-z.


A Short Update on the Use of Monoclonal Antibodies in COVID-19.

Vitiello A, Sabbatucci M, Ponzo A, Salzano A, Zovi A AAPS J. 2024; 26(2):30.

PMID: 38443725 DOI: 10.1208/s12248-024-00904-y.


References
1.
Frost B, Bardai F, Feany M . Lamin Dysfunction Mediates Neurodegeneration in Tauopathies. Curr Biol. 2016; 26(1):129-36. PMC: 4713335. DOI: 10.1016/j.cub.2015.11.039. View

2.
Liu C, Lee G, Jay D . Tau is required for neurite outgrowth and growth cone motility of chick sensory neurons. Cell Motil Cytoskeleton. 1999; 43(3):232-42. DOI: 10.1002/(SICI)1097-0169(1999)43:3<232::AID-CM6>3.0.CO;2-7. View

3.
Takei Y, Teng J, Harada A, Hirokawa N . Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol. 2000; 150(5):989-1000. PMC: 2175245. DOI: 10.1083/jcb.150.5.989. View

4.
Vitiello A, Ferrara F . Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr. 2021; 133(17-18):983-988. PMC: 8055751. DOI: 10.1007/s00508-021-01855-6. View

5.
Hua Q, He R, Haque N, Qu M, del Carmen Alonso A, Grundke-Iqbal I . Microtubule associated protein tau binds to double-stranded but not single-stranded DNA. Cell Mol Life Sci. 2003; 60(2):413-21. PMC: 11146073. DOI: 10.1007/s000180300034. View